Genmab A/S (GMAB)
51.37
-0.37
(-0.72%)
USD |
NASDAQ |
Nov 13, 16:00
52.12
+0.74
(+1.45%)
After-Hours: 06:09
Genmab Price to Book Value : 4.988 for Nov. 13, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 4.988 |
| November 12, 2026 | 5.024 |
| November 11, 2026 | 5.231 |
| November 10, 2026 | 5.250 |
| November 09, 2026 | 5.418 |
| November 06, 2026 | 5.208 |
| November 05, 2026 | 5.121 |
| November 04, 2026 | 5.352 |
| November 03, 2026 | 5.391 |
| November 02, 2026 | 5.333 |
| October 30, 2026 | 5.541 |
| October 29, 2026 | 5.485 |
| October 28, 2026 | 5.563 |
| October 27, 2026 | 4.338 |
| October 26, 2026 | 4.339 |
| October 23, 2026 | 4.252 |
| October 22, 2026 | 3.884 |
| October 21, 2026 | 3.842 |
| October 20, 2026 | 3.794 |
| October 19, 2026 | 3.738 |
| October 16, 2026 | 3.593 |
| October 15, 2026 | 3.672 |
| October 14, 2026 | 3.582 |
| October 13, 2026 | 3.551 |
| October 12, 2026 | 3.629 |
| Date | Value |
|---|---|
| October 09, 2026 | 3.600 |
| October 08, 2026 | 3.501 |
| October 07, 2026 | 3.559 |
| October 06, 2026 | 3.670 |
| October 05, 2026 | 3.736 |
| October 02, 2026 | 3.374 |
| October 01, 2026 | 3.355 |
| September 30, 2026 | 3.464 |
| September 29, 2026 | 3.565 |
| September 28, 2026 | 3.544 |
| September 25, 2026 | 3.540 |
| September 24, 2026 | 3.491 |
| September 23, 2026 | 3.483 |
| September 22, 2026 | 3.530 |
| September 21, 2026 | 3.477 |
| September 18, 2026 | 3.482 |
| September 17, 2026 | 3.461 |
| September 16, 2026 | 3.448 |
| September 15, 2026 | 3.423 |
| September 14, 2026 | 3.272 |
| September 11, 2026 | 3.254 |
| September 10, 2026 | 3.230 |
| September 09, 2026 | 3.311 |
| September 08, 2026 | 3.360 |
| September 04, 2026 | 3.368 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| Incyte Corp. | 4.373 |
| Ascendis Pharma A/S | 10.60 |
| Zealand Pharma A/S | 0.9113 |
| Bavarian Nordic A/S | 1.284 |
Price to Book Value Related Metrics
| PE Ratio | 44.01 |
| PS Ratio | 7.630 |
| Price to Free Cash Flow | 38.87 |
| Price | 51.37 |
| Earnings Yield | 2.27% |
| Market Cap | 31.59B |
| Operating PE Ratio | 24.91 |
| Normalized PE Ratio | 35.27 |